Healthcare Business - Page 2

FDA_logo

Where Merck and Pfizer’s Type 2 Diabetes Treatment Can Go From Here

Merck & Co. Inc. (NYSE: MRK) and Pfizer Inc. (NYSE: PFE) each saw their shares sink early on Monday after they gave an update on their type 2 diabetes treatment. ...
Read Full Story »
Depressed Senior Adult Man With Stacks of Papers and Envelopes

Why Analysts Are Looking at Valeant Pharma Differently After Earnings

Valeant Pharmaceuticals International Inc. (NYSE: VRX) saw its shares hit a multiyear low this past week. There was hope for a turnaround when Joe Papa took over as chief executive officer, but ...
Read Full Story »
graph

Wedbush Has 3 Biotech Stocks to Buy With Massive Upside Potential

Needless to say, the biotech world has had a very difficult 18 months. Even the biggest and the best companies, many of which trade cheaper than big pharmaceutical companies, have ...
Read Full Story »
Good heart health

Thursday’s Top Biopharma Movers

Although the health care sector has been attacked by the U.S. government in the past, it now has one of the brightest outlooks in 2017. Considering that the president aims to ...
Read Full Story »
bigger fish

RBC Says These Top Health Care Stocks Could Be 2017 Takeover Candidates

Another year, and another certainty that some companies, especially small and mid-cap, are going to be targets for mergers and acquisitions. The reasons are usually the same: Bigger large cap ...
Read Full Story »
Female patient on gurney

4 Biopharma Stocks Moving the Market on Wednesday

Markets have hit new intraday highs on Wednesday, continuing to climb in the wake of the White House announcements. Although the health care sector has been attacked by the U.S. ...
Read Full Story »
ashamed businessman

Why Valeant Missed the Mark Despite an Earnings Beat

When Valeant Pharmaceuticals International Inc. (NYSE: VRX) reported its fourth-quarter financial results before the markets opened on Tuesday, the company said that it had $1.26 in EPS and $2.4 billion ...
Read Full Story »
biotech word cloud

Short Sellers Hike Their Bets in Major Biotechs

The short interest data are out for the most recent settlement date, February 15. Generally speaking, companies within the biotech industry are considered to be a riskier group of stocks, ...
Read Full Story »
Prescription drugs

Why Short Sellers Are Making a Massive Bet in Major Pharma

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »
graph

How La Jolla’s Low Blood Pressure Treatment Is Driving New Highs

La Jolla Pharmaceutical Co. (NASDAQ: LJPC) saw its shares skyrocket on Monday after top-line results from its late-stage study of LJPC-501 in patients with catecholamine resistant hypotension. Ultimately, LJPC-501 posted ...
Read Full Story »
automatic inspection machine

Top Biopharma Movers of the Past Week

A few biopharma companies made massive runs this past week. The health care sector was in trouble over the past year, under fire from congressional hearings and politicians on the ...
Read Full Story »
Exit

Is There More Than Meets the Eye on Celgene’s President, COO Retirement?

Celgene Corp. (NASDAQ: CELG) had seen endless growth and a major stock acceleration in prior years. But that was then, and Wall Street only cares about the upside of the ...
Read Full Story »
Female patient on gurney

Is This the Turnaround Cempra Has Been Looking For?

Shares of Cempra Inc. (NASDAQ: CEMP) saw an incredible gain on Friday after the company announced the results from its late-stage trial for the treatment of patients with acute bacterial ...
Read Full Story »
automatic inspection machine

Large Cap Biotech Stocks to Buy May Be the Cheapest in Years

Almost every asset class is overbought now, and the few that aren’t — with the exception of one — have good reasons. Utilities and other income proxy stocks that were big in ...
Read Full Story »
child with cancer

With New Cash and Cancer Targets, Analyst Sees Almost 200% Upside in Sierra Oncology

Sierra Oncology Inc. (NASDAQ: SRRA) is far from a household name for investors who delve into health care, pharmaceuticals and biotech. In fact, Sierra would have to be considered quite ...
Read Full Story »